What does tesamorelin stand for?

Tesamorelin is the international non-proprietary name for a synthetic 44-amino-acid analog of growth hormone releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus. The developmental code was TH9507. The proprietary brand name is Egrifta (and Egrifta SV for the more recent sterile water variant). All four names describe the same compound.

What research applications use tesamorelin?

Tesamorelin is used in research as a tool to probe growth hormone axis biology with preserved pulsatility, visceral adipose tissue metabolism, lipid signalling, and liver fat biology. The Falutz NEJM 2007 trial and the Stanley JAMA 2014 trial provide the principal published clinical context. The compound's established clinical evidence base distinguishes it from most other research peptides.

Performance · Rx onlyTESA—03

Tesamorelin

teh·sah·moh·REH·linGHRH analogue — the clinically proven one

Growth-hormone-releasing therapy with phase-3 evidence behind it — visceral fat, recovery, and body composition, monitored against your labs.

Nightly micro-dose12-week courseIGF-1 at baseline · 6 · 12 wkPhysician-supervised

Check your eligibility Read the clinical reference →

The evidence−18%

Mean reduction in visceral adipose tissue at 26 weeks in phase 3 trials — tesamorelin is the most clinically validated GHRH analogue available. Your physician will be direct about what applies to your case.

Candidacy

Who this is for

Adults with stubborn visceral fat, declining recovery, or body-composition goals where labs support GH-axis therapy. Candidacy is decided by your physician against your history and IGF-1, never by a checkout flow.

Often appropriateCentral adiposity resistant to structured diet and trainingLow-normal IGF-1 with symptoms to matchRecovery and sleep degrading despite training

Not appropriateActive or recent malignancy — GH signalling is contraindicatedPregnancy or breastfeedingUntreated sleep apnoea or unexplained symptoms — investigate first

Measured, not promisedThe one with phase-3 trials behind it.

The program

How the program works

Day 0Free video consultation

A PRC-licensed physician reviews your goals, history, and whether this therapy is appropriate. If it isn't, you'll hear that instead.

Week 1Baseline labs & first dose

An at-home blood draw establishes your baseline. Your pen ships cold-chain once your physician signs the prescription.

Weeks 2–12Nightly dosing & check-ins

A small dose before bed, timed to your natural GH pulse. Video review at week 6, messaging in between.

Week 12Full review

IGF-1 and symptoms reviewed against baseline. Together you decide: continue, adjust, or taper off with a plan.

Included

What’s included

Single-patient pen, named prescriptioncGMP facility

Cold-chain delivery to your door1–2 days, Metro Manila

IGF-1 panels through the coursebaseline, wk 6, 12

Video reviews through the coursenamed physician

Sleep and training guidanceevery check-in

No prices on this site by design — your program is quoted in full after your consultation, before anything is dispensed.

Questions

Common questions

Sleep depth often shifts within weeks; body-composition changes are slower and tracked at your IGF-1 reviews. Your physician measures rather than promises.

Find out if this fits youFree 20-min video consultation

Book

The science

Stimulating release, not replacing it

GHRH receptor agonism

Tesamorelin binds the growth hormone releasing hormone receptor (GHRHR) on anterior pituitary somatotroph cells, stimulating the synthesis and pulsatile release of growth hormone. The full 44-amino-acid sequence allows close engagement with the native receptor.

Pulsatility preservation

Tesamorelin preserves the physiological pulsatility of growth hormone secretion, in contrast to exogenous GH administration which suppresses endogenous pulsatile release. The pulsatility preservation is mechanistically relevant to downstream IGF-1 signalling.

N-terminal stabilisation

The trans-3-hexenoic acid modification at the N-terminus protects tesamorelin from rapid degradation by dipeptidyl peptidase-IV (DPP-IV), the enzyme that limits native GHRH plasma half-life to roughly seven minutes. The modification is the structural reason tesamorelin has a clinically useful pharmacokinetic profile.

Visceral adipose effects

Falutz and colleagues (N Engl J Med, 2007;357(23):2359-2370) reported reduced visceral adipose tissue measured by CT scan in HIV-infected adults with abdominal lipodystrophy. The visceral fat reduction is the basis for the FDA approval indication.

Tesamorelin is also searched as TH9507, Egrifta, GHRH (1-44) analog.

Tesa­morelin